Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

201 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Farmer H, et al. Among authors: lord cj. Nature. 2005 Apr 14;434(7035):917-21. doi: 10.1038/nature03445. Nature. 2005. PMID: 15829967
Phenotypic effects of heterozygosity for a BRCA2 mutation.
Warren M, Lord CJ, Masabanda J, Griffin D, Ashworth A. Warren M, et al. Among authors: lord cj. Hum Mol Genet. 2003 Oct 15;12(20):2645-56. doi: 10.1093/hmg/ddg277. Epub 2003 Aug 19. Hum Mol Genet. 2003. PMID: 12928478
DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells.
Gudmundsdottir K, Lord CJ, Witt E, Tutt AN, Ashworth A. Gudmundsdottir K, et al. Among authors: lord cj. EMBO Rep. 2004 Oct;5(10):989-93. doi: 10.1038/sj.embor.7400255. Epub 2004 Sep 10. EMBO Rep. 2004. PMID: 15359272 Free PMC article.
BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.
McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. McCabe N, et al. Among authors: lord cj. Cancer Biol Ther. 2005 Sep;4(9):934-6. doi: 10.4161/cbt.4.9.2141. Epub 2005 Sep 1. Cancer Biol Ther. 2005. PMID: 16251802
Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.
Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A, Hartley JA, Hochhauser D. Friedmann BJ, et al. Among authors: lord cj. Mol Cancer Ther. 2006 Feb;5(2):209-18. doi: 10.1158/1535-7163.MCT-05-0239. Mol Cancer Ther. 2006. PMID: 16505093
Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.
Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A. Tutt AN, et al. Among authors: lord cj. Cold Spring Harb Symp Quant Biol. 2005;70:139-48. doi: 10.1101/sqb.2005.70.012. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869747
Targeting the double-strand DNA break repair pathway as a therapeutic strategy.
Lord CJ, Garrett MD, Ashworth A. Lord CJ, et al. Clin Cancer Res. 2006 Aug 1;12(15):4463-8. doi: 10.1158/1078-0432.CCR-06-1269. Clin Cancer Res. 2006. PMID: 16899589 Review.
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. McCabe N, et al. Among authors: lord cj. Cancer Res. 2006 Aug 15;66(16):8109-15. doi: 10.1158/0008-5472.CAN-06-0140. Cancer Res. 2006. PMID: 16912188
RAD51, BRCA2 and DNA repair: a partial resolution.
Lord CJ, Ashworth A. Lord CJ, et al. Nat Struct Mol Biol. 2007 Jun;14(6):461-2. doi: 10.1038/nsmb0607-461. Nat Struct Mol Biol. 2007. PMID: 17549079 No abstract available.
The proteasome is involved in determining differential utilization of double-strand break repair pathways.
Gudmundsdottir K, Lord CJ, Ashworth A. Gudmundsdottir K, et al. Among authors: lord cj. Oncogene. 2007 Nov 29;26(54):7601-6. doi: 10.1038/sj.onc.1210579. Epub 2007 Jun 11. Oncogene. 2007. PMID: 17563742
201 results
Jump to page
Feedback